Gordon Michael S 的 Form 4 申報
ProMIS Neurosciences Inc.（PMN），2025/7/29 申報
- 申報編號
- 0001104659-25-071858
- 申報時間
- 2025/7/29
- 交易日
- 2025/7/25-7/29
- 申報延遲
- 4 天
- 10b5-1 計畫
- 沒有勾選
這份申報列了 3 筆非衍生性交易、4 筆衍生性交易。交易後 4 天申報。
這份申報後來被修正申報 0001104659-25-078631（2025/8/14）取代，網站的交易表改用修正後的版本。
申報人
一份 Form 4 可以有好幾位申報人，例如本人與他控制的基金。各交易表上顯示的是第一位。
| 申報人 | 與公司的關係 |
|---|---|
| Gordon Michael SCIK 0001034608 | 持股 10% 以上大股東 |
非衍生性證券（表 I）
普通股等股票的取得與處分，每一列是申報上的一筆。
衍生性證券（表 II）
選擇權、認股權證、限制型股票單位等。股數是標的股票的股數；單價與金額是衍生證券本身的價格，交易後持有是衍生證券的單位數。
| 交易日 | 證券 | 交易 | 標的股數 | 單價 | 金額 | 交易後持有 | 持有方式 | 旗標 |
|---|---|---|---|---|---|---|---|---|
| 2025/7/25 | Common Shares | X行使價內選擇權處分 | −119,800 | $0.00 | $0 | 345,316 | 間接 | |
| 2025/7/25 | Common Shares | X行使價內選擇權處分 | −119,800 | $0.00 | $0 | 345,316 | 間接 | |
| 2025/7/25 | Common Shares | X行使價內選擇權處分 | −119,800 | $0.00 | $0 | 345,316 | 間接 | |
| 2025/7/29 | Common Shares | P買進取得 | +539,100 | –F5 | – | 539,100 | 間接 |
附註與備註
本站收錄交易價格引用的附註、修正申報（Form 4/A）的全部附註，以及申報的備註。其他附註，例如間接持有的方式、交易計畫的細節，請看 SEC EDGAR 上的原文。
- F1
On July 25, 2025, Title 19 Promis exercised 119,800 Tranche A purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83158 per share. The remainder of these warrants are currently exercisable and expire on the earlier of (i) 18 months of the issue date and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 6-month data from the cohorts treated with single ascending doses of PMN310.
表 I 有 1 筆交易的價格引用這則附註。
- F3
On July 25, 2025, Title 19 Promis exercised 119,800 Tranche B purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83158 per share. The remainder of these warrants are currently exercisable and expire on the earlier of (i) 30 months of the issue date and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 12-month data from the cohorts treated with single ascending doses of PMN310.
表 I 有 1 筆交易的價格引用這則附註。
- F4
On July 25, 2025, Title 19 Promis exercised 119,800 Tranche C purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.50 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83158 per share. The remainder of these warrants are currently exercisable and expire on July 31, 2029.
表 I 有 1 筆交易的價格引用這則附註。
- F5
On July 29, 2025, Title 19 Promis acquired 539,100 warrants, each exercisable to purchase one Common Share, at an exercise price of $1.25 per share. The purchase price for each warrant was $0.1875 per share. The warrants are currently exercisable and expire five years after the date of issuance.
表 II 有 1 筆交易的價格引用這則附註。